Published in Immunol Rev on August 01, 2003
MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity (2008) 5.03
AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell (2008) 4.13
Myc dynamically and preferentially relocates to a transcription factory occupied by Igh. PLoS Biol (2007) 3.82
Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes. Cell (2011) 3.65
AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell (2009) 2.75
AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J Exp Med (2008) 2.10
PTIP promotes chromatin changes critical for immunoglobulin class switch recombination. Science (2010) 2.05
Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr (2008) 2.01
Mcl-1 is essential for the survival of plasma cells. Nat Immunol (2013) 1.73
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia (2014) 1.56
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. Nature (2017) 1.43
Organization of transcription. Cold Spring Harb Perspect Biol (2010) 1.20
Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest (2004) 1.10
A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One (2012) 1.07
IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood (2009) 1.07
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J (2013) 1.03
Restricting activation-induced cytidine deaminase tumorigenic activity in B lymphocytes. Immunology (2009) 0.98
NOTCH is part of the transcriptional network regulating cell growth and survival in mouse plasmacytomas. Cancer Res (2008) 0.98
53BP1 alters the landscape of DNA rearrangements and suppresses AID-induced B cell lymphoma. Mol Cell (2013) 0.93
Activation-induced cytidine deaminase in antibody diversification and chromosome translocation. Adv Cancer Res (2012) 0.92
Targeting the oncogene B lymphoma deregulator IgH 3' regulatory region does not impede the in vivo inflammatory response in mice. Oncoscience (2014) 0.91
Effects of acute and chronic inflammation on B-cell development and differentiation. J Invest Dermatol (2009) 0.90
A mutant collagen XIII alters intestinal expression of immune response genes and predisposes transgenic mice to develop B-cell lymphomas. Cancer Res (2008) 0.88
Mouse model of endemic Burkitt translocations reveals the long-range boundaries of Ig-mediated oncogene deregulation. Proc Natl Acad Sci U S A (2012) 0.88
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics (2007) 0.86
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer (2010) 0.84
Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. Blood (2011) 0.84
The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia (2012) 0.84
Genomic instability and mouse microRNAs. Toxicol Mech Methods (2011) 0.83
Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity. Nat Rev Immunol (2016) 0.82
Constitutive NF-kappaB activation confers interleukin 6 (IL6) independence and resistance to dexamethasone and Janus kinase inhibitor INCB018424 in murine plasmacytoma cells. J Biol Chem (2011) 0.82
Heterologous tissue culture expression signature predicts human breast cancer prognosis. PLoS One (2007) 0.81
Distinct granuloma responses in C57BL/6J and BALB/cByJ mice in response to pristane. Int J Exp Pathol (2010) 0.81
Msh6 protects mature B cells from lymphoma by preserving genomic stability. Am J Pathol (2010) 0.80
Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. ISRN Hematol (2013) 0.79
Oncogenic Myc translocations are independent of chromosomal location and orientation of the immunoglobulin heavy chain locus. Proc Natl Acad Sci U S A (2012) 0.79
Anaplastic plasmacytomas: relationships to normal memory B cells and plasma cell neoplasms of immunodeficient and autoimmune mice. J Pathol (2010) 0.79
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res (2014) 0.78
A der(8)t(8;11) chromosome in the Karpas-620 myeloma cell line expresses only cyclin D1: yet both cyclin D1 and MYC are repositioned in close proximity to the 3'IGH enhancer. DNA Repair (Amst) (2008) 0.77
Translocation of an antibody transgene requires AID and occurs by interchromosomal switching to all switch regions except the mu switch region. Eur J Immunol (2011) 0.77
Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained. Blood (2014) 0.77
Differential development of oil granulomas induced by pristane injection in galectin-3 deficient mice. BMC Immunol (2015) 0.77
Efficient role of IgH 3' regulatory region deficient B-cells in the development of oil granulomas. Oncotarget (2016) 0.76
Effects of Gene Dose, Chromatin, and Network Topology on Expression in Drosophila melanogaster. PLoS Genet (2016) 0.75
Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia. J Pathol (2010) 0.75
Bazedoxifene enhances the anti-tumor effects of cisplatin and radiation treatment by blocking IL-6 signaling in head and neck cancer. Oncotarget (2016) 0.75